Stock Scorer

Crescent Biopharma, Inc. (CBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 3.5M 7M 10.5M Q3 '15: 0 Q4 '15: 35.4K Q3 '16: 18.5K Q4 '16: 0 Q1 '20: 9M Q2 '20: 0 Q3 '20: 1M Q4 '20: 162.9K Q1 '21: 1.1M Q2 '21: 142 Q3 '21: 86.6K Q4 '21: 17.6K Q1 '22: 0 Q2 '22: 75K Q3 '22: 0 Q4 '22: 0 Q1 '25: 0 Q2 '25: 0 Q1 '26: 1M Q2 '26: 0 Q4 '15 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '25 Q2 '26

Operating Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -17.3M Q4 '21: -17.4M Q1 '22: -14.7M Q2 '22: -13.4M Q3 '22: -8.8M Q4 '22: -10.6M Q1 '23: -10.9M Q2 '23: -8.9M Q3 '23: -9.8M Q4 '23: -9.6M Q1 '24: -11.1M Q2 '24: -10.4M Q3 '24: -11.2M Q4 '24: -14.6M Q1 '25: -14.2M Q2 '25: -21M Q3 '25: -25.9M Q4 '25: -91.5M Q1 '26: -24.7M Q2 '26: -26.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-27M -18M -9M 0 9M 18M 27M Q3 '21: -17.3M Q4 '21: -17.4M Q1 '22: -14.7M Q2 '22: -13.3M Q3 '22: -8.5M Q4 '22: -10.2M Q1 '23: -10.4M Q2 '23: -8.3M Q3 '23: -9.2M Q4 '23: -9.1M Q1 '24: -10.7M Q2 '24: -10.1M Q3 '24: -9.8M Q4 '24: -15.2M Q1 '25: -15.1M Q2 '25: -21.8M Q3 '25: -24.6M Q4 '25: -23.3M Q1 '26: -23.3M Q2 '26: -24.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-30M -20M -10M 0 10M 20M 30M Q3 '21: -16.9M Q4 '21: -12.8M Q1 '22: -13.7M Q2 '22: -16.2M Q3 '22: -8.6M Q4 '22: -7.9M Q1 '23: -11.6M Q2 '23: -7M Q3 '23: -8.7M Q4 '23: -7.6M Q1 '24: -10.5M Q2 '24: -8.9M Q3 '24: -8M Q4 '24: -6.3M Q1 '25: -10.9M Q2 '25: -16.4M Q3 '25: -17.5M Q4 '25: -26.7M Q1 '26: -8.9M Q2 '26: -19.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-30M -20M -10M 0 10M 20M 30M Q3 '21: -17M Q4 '21: -12.8M Q1 '22: -13.7M Q2 '22: -16.3M Q3 '22: -8.6M Q4 '22: -7.9M Q1 '23: -11.6M Q2 '23: -7M Q3 '23: -8.7M Q4 '23: -7.6M Q1 '24: -10.5M Q2 '24: -8.9M Q3 '24: -8M Q4 '24: -6.3M Q1 '25: -10.9M Q2 '25: -16.5M Q3 '25: -18.1M Q4 '25: -26.9M Q1 '26: -9.1M Q2 '26: -19.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '13: 946.4K Q1 '14: 17.2M Q2 '14: 20.2M Q3 '14: 18.9M Q2 '15: 20.2M Q3 '15: 19M Q2 '16: 19.8M Q1 '21: 50.7M Q2 '21: 51.5M Q3 '21: 51.6M Q1 '22: 52.3M Q2 '22: 52.4M Q3 '22: 52.4M Q1 '23: 64.5M Q2 '23: 64.3M Q3 '23: 64.3M Q1 '24: 64.5M Q2 '24: 64.5M Q3 '24: 64.5M Q1 '25: 64.5M Q1 '14 Q2 '15 Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q1 '19: -1.18 Q2 '19: -1.29 Q3 '19: -1.33 Q4 '19: -1.35 Q1 '20: -1.20 Q2 '20: -1.15 Q3 '20: -1.13 Q4 '20: -1.12 Q1 '21: -1.22 Q2 '21: -1.18 Q3 '21: -1.23 Q4 '21: -1.23 Q1 '22: -1.23 Q2 '22: -1.20 Q3 '22: -1.02 Q4 '22: -0.88 Q1 '23: -0.77 Q2 '23: -0.65 Q3 '23: -0.63 Q4 '23: -0.58 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for CBIO: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.